Last update: July 1, 2015
Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.
Higher excretion into breast milk than other related antidepressant drugs. The active metabolite called Norfluoxetine has a longer half-life (4 to 16 days). Like other antidepressant drugs may induce hyperprolactinemia and galactorrhea.
Few cases of colicky pain, irritability, insomnia, anorexia and slow weight gain have been described. However, most reported cases have failed to show harm effect outside the newborn period. Large experience with the use of Fluoxatine did not find harm effect on weight gain and neurological development of infants either at short or long term.
Most problems have appeared in the early neonatal period either in newborns or premature infants whose mothers were on Fluoxetine during pregnancy. Stop or switch to other medication either at some days before delivery or in the first month postpartum would be recommended. Same considerations should be done in case of prematurity, however, medication must be continued if necessary.
Women on anti-depressant treatment are in need of stronger support because of higher risk of breastfeeding failure.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana from Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM